Reminyl: profile and news

Novartis Drug Works for Parkinson's-Linked Dementia, US Says 16 May 2006
Doctors often give Exelon, Pfizer Inc.'s Aricept and Reminyl by Johnson & Johnson and Shire Pharmaceuticals Group Plc to Parkinson's patients with dementia. ... - Bloomberg

New Prescription Pain Treatment Jurnista(TM) Prolonged-Release ... May 15, 2006
...r) (anaemia), SPORANOX(R) (fungal infections), VELCADE(R) (multiple myeloma), PARIET(r) (gastroenterology), TOPAMAX(r) (epilepsy), REMINYL(r) (Alzheimer's ... - PR Newswire UK (press release),

Shire Announces Good Start to the Year and Guidance Reaffirmed Apr 27, 2006
...capsules) FOSRENOL(R) (lanthanum carbonate) GENE-ACTIVATED(R) (glucocerebrosidase) LODINE (R) (etodolac) MESAVANCE(TM) (mesalamine) REMINYL(R) (galantamine ... - PR Newswire (press release),

Alzheimer's drugs help: Study Apr 19, 2006
...dressed unprompted. Half the subjects were given Reminyl, a cholinesterase inhibitor, for four months and the other half a placebo. A ... - Ottawa Sun,

MediciNova, Inc. Appoints Arlene M. Morris and Alan W. Dunton to ... May 11, 2006
...of experience are marked by the development and approval of the prescription drugs Levaquin(R) (antibiotic), TOPAMAX(R) (migraine), Reminyl(R) (Alzheimer's ... - International News Service,

Treating Cognition and Function in Patients With Alzheimer Disease May 10, 2006
...large-scale trials involving all agents presently available within the class (donepezil [Aricept], rivastigmine [Exelon], and galantamine [Reminyl, Razadyne]). ... - Psychiatric Times,

Apathy and Its Treatment in Alzheimer's Disease and Other ... May 5, 2006
Erkinjuntti T (2002), Treatment options: the latest evidence with galantamine (Reminyl). J Neurol Sci 203-204:125-130. Feldman H, Gauthier S, Hecker J et al. ... - Psychiatric Times,

Hospitals may have to close to pay for new drugs, says Hewitt Apr 22, 2006
...in western Europe to introduce new treatments.On the continent, Alzheimer's sufferers at all stages of the disease get new drugs such as Reminyl, which Nice ... - Independent,

28-site Trial Studying Chinese Herb As Alzheimer's Treatment Apr 29, 2006
...mild to moderate AD The trial focuses on individuals who have not found currently approved cholinesterase inhibitors (including Aricept, Reminyl, Exelon or ... - Medical News Today (press release),

Other information

Indication
For the treatment of mild to moderate dementia of the Alzheimer's type.

Pharmacology
Galantamine is a parasympathomimetic, specifically, a reversible cholinesterase inhibitor. Galantamine is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. Galantamine is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. If this proposed mechanism of action is correct, Galantamine's effect may lessen as the disease process advances and fewer cholinergic neurons remain functionally intact. There is no evidence that Galantamine alters the course of the underlying dementing process.

Mechanism Of Action
Galantamine's proposed mechanism of action involves the increase of the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase.

Drug Category
Nootropic Agents; Parasympathomimetics; Parasympathomimetics; ATC:N06DA04

Brand Names/Synonyms
Galantamin; Galantamine; Galanthamine; Galanthamine Base; Galanthamine Hydrobromide; Jilkon; Lycoremin; Lycoremine; Reminyl

Dosage Forms
CAPSULE, EXTENDED RELEASE

Absorption
Not Available

Interactions
Not Available

Chemical IUPAC Name
(4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol

Chemical Formula
C17H21NO3

Half Life
7 hours

Drug Type
Approved Drug

# Accession No
APRD00206

CAS Registry Number
357-70-0